Vol.52 No.12 December 2004

Status and prospects for antibacterial agent development

Morimasa Yagisawa

Jpn. J. Chemother. 52 (12): 761-770, 2004

Surveillance of susceptibility of 2,228 clinical isolates to gatifloxacin and various antimicrobial agents

Keizo Yamaguchi, Nobuhiko Furuya, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Mitsuo Kaku, Yuko Abe, Jun Igari, Toyoko Oguri, Hisashi Baba, Hitoshi Yoshimura, Kiyoharu Yamanaka, Satoshi Ichiyama, Nobuchika Kusano, Naoko Murao, Junko Ono, Chika Narita, Kaoru Okada, Masami Ishida, Yoichi Hirakata and Junichi Matsuda

Jpn. J. Chemother. 52 (12): 771-786, 2004

Sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA) without effects of vancomycin (VCM), teicoplanin (TEIC) and arbekacin (ABK) treated successfully and safely with intravenous administration of linezolid (LZD)

Shinya Ohkouchi, Kazunori Gomi, Yutaka Tokue, Toshiaki Kikuchi, Shigeru Fujimura, Toshihiro Nukiwa and Akira Watanabe

Jpn. J. Chemother. 52 (12): 787-792, 2004

Usefulness of levofloxacin at 200 mg b.i.d. for suspected pneumococcal pneumonia

Yoshihito Niki, Toshiharu Matsushima, Keizo Yamaguchi, Shigeru Kohno, Akira Watanabe, Shigeki Odagiri, Nobuki Aoki and Atsushi Saito

Jpn. J. Chemother. 52 (12): 793-803, 2004